Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Current Assets (2022 - 2025)

Historic Current Assets for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $288.3 million.

  • Zentalis Pharmaceuticals' Current Assets fell 2797.31% to $288.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.3 million, marking a year-over-year decrease of 2797.31%. This contributed to the annual value of $386.1 million for FY2024, which is 2227.66% down from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Current Assets of $288.3 million as of Q3 2025, which was down 2797.31% from $311.6 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Current Assets peaked at $563.9 million during Q2 2023, and registered a low of $288.3 million during Q3 2025.
  • Its 4-year average for Current Assets is $421.8 million, with a median of $433.9 million in 2022.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Current Assets surged by 3616.01% in 2023, and later crashed by 3194.17% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Current Assets stood at $451.9 million in 2022, then increased by 9.91% to $496.7 million in 2023, then dropped by 22.28% to $386.1 million in 2024, then fell by 25.32% to $288.3 million in 2025.
  • Its last three reported values are $288.3 million in Q3 2025, $311.6 million for Q2 2025, and $342.9 million during Q1 2025.